No Data
Mesoblast's Cell Therapy Shows Improved Outcomes in Heart Disease Patients in Phase 3 Study
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Vanguard Australian Shares Index ETF Has Lifted 20% in a Year. Which Stocks Have Contributed Most to Its Rise?
Mesoblast Limited's (ASX:MSB) 17% Gain Last Week Benefited Both Retail Investors Who Own 54% as Well as Insiders
3 ASX 300 Stocks up by More Than 300% in a Year
Up 427% This Year, Why Today Is a Big Day for Mesoblast Shares
